<DOC>
	<DOCNO>NCT01119937</DOCNO>
	<brief_summary>This 52-week , multi-center , randomize , open label , parallel group study assess long term safety tolerability once-daily NVA237 , use tiotropium active control , Japanese patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Long Term Safety Tolerability NVA237 Versus Tiotropium Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients moderate severe stable COPD ( Stage II Stage III ) accord Gold Guideline 2008 . Current exsmokers smoke history least 10 pack year . Patients postbronchodilator FEV1 â‰¥30 % &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 0.7 Visit 2 ( day 7 ) Pregnant woman nurse mother woman childbearing potential use acceptable method contraception Patients require long term oxygen therapy Patients low respiratory tract infection within 6 week prior Visit 1 Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients known history diagnosis alpha1 antitrypsin deficiency Patients active phase supervise pulmonary rehabilitation program Patients contraindicate tiotropium ipratropium treatment show untoward reaction inhale anticholinergic agent Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>NVA237</keyword>
</DOC>